Show simple item record

Trends in Genotypic HIV-1 Antiretroviral resistance between 2006 and 2012 in South African Patients receiving first- and second line antiretroviral treatment regimens

Trends in Genotypic HIV-1 Antiretroviral resistance between 2006 and 2012 in South African Patients receiving first- and second line antiretroviral treatment regimens

dc.contributor.authorVan Zyl, Gert U.
dc.contributor.authorLiu, Tommy F.
dc.contributor.authorClaassen, Mathilda
dc.contributor.authorEngelbrecht, Susan
dc.contributor.authorde Oliveira, Tulio
dc.contributor.authorPreiser, Wolfgang
dc.contributor.authorWood, Natasha T.
dc.contributor.authorTravers, Simon A.
dc.contributor.authorShafer, Robert W.
dc.date.accessioned2017-02-17T09:55:18Z
dc.date.available2017-02-17T09:55:18Z
dc.date.issued2013
dc.identifier.citationVan Zyl, Gert U. (2013). Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. PLoS ONE 8(6):e67188
dc.identifier.citationVan Zyl, Gert U. (2013). Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. PLoS ONE 8(6):e67188en_US
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10566/2544
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0067188
dc.description.abstractSouth Africa's national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted lopinavir (LPV/r)-containing therapy.
dc.description.abstractSouth Africa's national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted lopinavir (LPV/r)-containing therapy.en_US
dc.languageen
dc.language.isoenen_US
dc.publisherUniversity of the Western Cape
dc.publisherPublic Library of Science -- PLoSen_US
dc.rights© 2013 Van Zyl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.subjectGenotypic HIV-1
dc.subjectAntiretroviral resistance
dc.subjectSouth Africa
dc.subjectGenotypic HIV-1en_US
dc.subjectAntiretroviral resistanceen_US
dc.subjectSouth Africaen_US
dc.titleTrends in Genotypic HIV-1 Antiretroviral resistance between 2006 and 2012 in South African Patients receiving first- and second line antiretroviral treatment regimens
dc.titleTrends in Genotypic HIV-1 Antiretroviral resistance between 2006 and 2012 in South African Patients receiving first- and second line antiretroviral treatment regimensen_US
dc.typeArticle
dc.typeArticleen_US
dc.privacy.showsubmitterFALSE
dc.status.ispeerreviewedTRUE
dc.description.accreditationWeb of Science


Files in this item

Thumbnail
Name:
Van Zyl_Trends in Genotypic ...
Size:
276.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record